Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar icemeta (73.43) Submitted: 12/3/2007 9:17:24 PM : Outperform Start Price: $7.46 HALO Score: +17.03

Explosive drug collaboration, $100 million cash, no debt, director just bought 20% of stock, incredible market opportunity, my largest position

Featured Broker Partners


Advertisement